Biography
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalizedwell-being and clinical care. He is also Professor of Pharmacology Chemical Biology and Human Genetics at UPMC Hillman Cancer Center. Dr. Leereceived B. Sc. and Ph. D. degrees in England, and came to San Antonio, Texasfor his postdoctoral studies. He was subsequently recruited to Baylor College of Medicine and to the University of Pittsburgh in 2010. The goalof Dr. Lees research laboratory is to translate basic cell and molecularresearch findings into the understanding and treatment of breast cancer. Dr Lee has published over 180 peer reviewed research articles. His laboratoryis supported by funding from the NIH, Department of Defense, Susan G. Komenfor the Cure, Breast Cancer Research Foundation, and other sources.

Biography
Dr. Dennis J. Slamon is a distinguished oncologist and researcher known for his groundbreaking breast cancer work since the late 1990s. His pioneering research led to trastuzumab (Herceptin), a targeted therapy that revolutionized treatment of HER2-positive breast cancer, significantly improving survival rates for this aggressive subtype. Dr. Slamon has continued to transform cancer research, advancing targeted therapies and precision medicine to improve patient outcomes. His work focuses on identifying molecular targets for new therapies, tailoring treatments to the specific genetic alterations in tumors. His efforts have impacted not only breast cancer but other cancers with similar molecular profiles. Throughout his career, Dr. Slamon has received prestigious awards, including the 2019 Lasker-De Bakey Clinical Medical Research Award and the 2024 Szent-Györgyi Prize for Progress in Cancer Research. He remains a leader in oncology, dedicated to advancing innovative treatments and improving the lives of cancer patients worldwide.

Biography
Dr. Pedram Razavi is a medical oncologist and physician-scientist at Memorial Sloan Kettering Cancer Center (MSK), specializing in precision oncology for breast cancer. He serves as Director of the Breast Cancer Translational Program and Molecular Tumor Board, and Director of Liquid Biopsy and Cancer Genomics for the MSK Biomarker Development Program. His research focuses on integrative clinicogenomic approaches and circulating tumor biomarkers to characterize breast cancer at both systemic and molecular levels and to expand the clinical utility of liquid biopsy technologies. Dr. Razavi earned his MD from Tehran University of Medical Sciences and his MPH and PhD in cancer epidemiology from the University of Southern California. He completed a postdoctoral fellowship at the Channing Laboratory, an internal medicine residency at USC, and a medical oncology fellowship at MSK, where he also conducted postdoctoral research in cancer genomics in the lab of Dr. José Baselga.

Biography
Mark Stewart works at Friends of Cancer Research, a Washington, DCbased organization that brings together partners across healthcare to drive advances in science, policy, and regulation that accelerate the development of cancer therapies and diagnostics. At Friends, he leads collaborative projects that create frameworks for incorporating novel clinical trial endpoints, advancing ctDNA and liquid biopsy applications, integrating real-world evidence, and applying innovative designs to make trials more efficient and representative. His work also explores emerging technologies such as AI-based tools to enhance oncology drug development, clinical trial design, and data interpretation. Through multi-stakeholder partnerships with regulators, academia, industry, and patient groups, he helps develop consensus-driven solutions that overcome barriers in drug development. These efforts have informed national policy discussions, contributed to regulatory innovation, and translated promising innovations into meaningful progress for people with cancer.

Biography
Dr. David Miyamoto is a physician scientist in the Krantz Family Center for Cancer Research at the Mass General Brigham Cancer Institute and Harvard Medical School. His translational research efforts focus on the development of novel biomarkers to guide bladder and prostate cancer therapy and improve the individualized care of each patient, with an emphasis on liquid biopsies. He has authored over 60 publications in peer-reviewed scientific journals including Science, Cell, Cancer Discovery, Nature Communications, and Lancet Oncology. His research has been supported by grants from the NIH, U. S. Department of Defense, Prostate Cancer Foundation, and Radiation Oncology Institute. Dr. Miyamoto is also a board-certified radiation oncologist specializing in treating patients with genitourinary malignancies. After receiving his AB (Chemistry), MD, and PhD (Cell and Developmental Biology) degrees from Harvard University, he completed his internship in Internal Medicine at the Brigham Women's Hospital and his residency in the Harvard Radiation Oncology Program.

Biography
Dr. De Micheles research focuses on preventing breast cancer recurrence and metastasis with targeted drug combinations to eliminate disseminated tumor cells. Since 2005, she has been the Co-Leader of the Breast Cancer Research Program in the Abramson Cancer Center, where she also directs both the Breast Cancer Clinical Research Unit and the Breast Cancer TRACR Biobank. Dr. De Michele has authored over 130 publications in high-impact journals such as NEJM and JAMA and has been funded by the NIH, NCI, DOD and Stand Up to Cancer. She was recently awarded the 2023 Gianni Bonadonna Breast Cancer Award from A SCO and The Conquer Cancer Foundation.

Biography
GI oncologist but has a long standing background and interest in global health, having spent time in several African countries, Haiti and India. Most recently, at MGH, she co-founded and co-leads a program called POETIC ( Program for Enhanced Training in Cancer (POETIC)) This fellowship exchange program, conducted in collaboration with Beth Israel Deaconess Medical Center Cancer Center and Lowell Schnipper, MD, trains clinical oncology fellows from the University of Cape Town in South Africa and Ocean Road Cancer Center in Tanzania.

Biography
Dr. Halla Nimeiri serves as the Chief Development Officer of Oncology at Tempus. Prior to Tempus, she held clinical development positions at Foundation Medicine and AbbVie. Dr. Nimeiri is a dedicated oncologist. She brings expertise in clinical trial design, drug development, and precision oncology. Dr. Nimeiri is an active academic clinician at Feinberg School of Medicine, where she provided transformative patient care for over 10 years. Dr. Nimeiri earned her dual fellowship in Hematology Oncology from The University of Chicago.

Biography
Dr. Liu brings a wealth of experience in developing blood-based biomarkers to predict treatment benefit and outcomes in solid tumors and in developing novel therapeutics to improve survival, with a particular focus in breast cancer. She chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology. She also co-chaired the Correlative Science Working Group and led several multi-institutional clinical trials through the Translational Breast Cancer Research Consortium. Dr. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic in Rochester, MN. In her role at Mayo, she also held a dual appointment in the Department of Laboratory Medicine and Pathology and served as co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine.

Biography
Hilary Gee Goeckner is director of state and local campaigns for the American Cancer Society Cancer Action Network (A CS CAN), the advocacy affiliate of the American Cancer Society. In this role she leads work with A CS CAN staff and coalition partners across the country to improve access to comprehensive biomarker testing, clinical trials, fertility preservation and other health care access issues. Prior to this role, Hilary served as the Kansas government relations director for A CS CAN. Before joining A CS CAN, Hilary served as director of health policy at Kansas Action for Children. She holds a bachelors degree in anthropology and global health from Williams College and a masters degree in social work from Boston College. She lives in San Diego with her husband and two children.

Biography
Sally Werner is the CEO of Cancer Support Community (CSC), a global nonprofit dedicated to supporting individuals impacted by cancer. With over 25 years of experience as an oncology nurse and healthcare administrator, she has led clinical and operational efforts across hospitals, cancer service lines, and community-based programs. Passionate about innovation, supportive cancer care, and mission-driven leadership, she has enjoyed the last eight years at CSC. Sally lives in the Pacific Northwest with her husband and enjoys family time and the outdoors.

Biography
Dr. Bien-Willner is the Medical Director of the MolDX program at Palmetto GBA, a Medicare Administrative Contractor (MAC). He is a leader in the Precision Medicine space and practices as a Board-certified Anatomic Pathologist and Molecular Genetic Pathologist. Throughout his career, he has been active in research, development, and advancement of molecular diagnostic services, specifically next generation sequencing. He hasworkedclosely with clinicians to develop clear clinical diagnostic andtreatmentpathways directing Precision Medicine programs for communitycancercenters. Dr. Bien-Willner received his MD and PhD degrees from Baylor College of Medicine, with a PhD in Human Molecular Genetics. Hecompletedhis residency, fellowship, and attained a faculty appointment at Washington University in St. Louis prior to leadership roles in laboratoryand biotechcompanies before joining Palmetto GBA.

Biography
Maximilian Diehn received his Bachelors Degree in Biochemical Sciencesfrom Harvard College and his M. D. Ph. D. in Biophysics from Stanford University. He is a board certified Radiation Oncologist and specializes in the treatment of lung cancers. Dr. Diehns current research program spanslaboratory, translational, and clinical studies. His areas of interestinclude cancer genomics, stem cell biology, and lung cancer biology. Hiswork has been recognized with a variety of awards, including the VFoundation Scholar Award, the Sidney Kimmel Scholar Award, the Doris Duke Clinical Scientist Development Award, and the NIH Directors New Innovator Award. His group has developed an ultra sensitive and specific method fordetection of circulating tumor DNA called CAPP-Seq. Current work is focusedon applying CAPP-Seq to a range of clinical contexts, with an emphasis ontumor heterogeneity and minimal residual disease.

Biography
Luca Quagliata is the Vice President and Global Head of Medical Affairs for Thermo Fisher's Clinical Sequencing and Oncology Division. He's also a Venture Partner at xGEN VC-Fund, and serves on the boards of A CMA andIQNPath. Previously, he held key positions at the University Hospital of Basel.

Biography
Christopher Lieu, MD, is a Professor of Medicine in the Division of Medical Oncology, and Associate Director for Clinical Research at the University of Colorado School of Medicine in Aurora. He trained in internal medicine at the University of Colorado, where he also served as a Chief Medical Resident. He completed his fellowship training in medical oncology at the University of Texas MD Anderson Cancer Center in Houston and served as the Chief Medical Oncology Fellow. He currently serves as the Associate Director for Clinical Research and Director of GI Medical Oncology at the University of Colorado Cancer Center, serves on the FDA Oncologic Drugs Advisory Committee, the National Cancer Institute Colon Cancer Task Force, the National Comprehensive Cancer Network (NCCN) Panel for Neuroendocrine Cancers, and the Vice-Chair of the NCCN Board of Directors.

Biography
Dr. Daniel De Carvalho is a leading cancer biologist recognized for pioneering cfDNA methylome profiling (cf MeDIP-seq), the first method to demonstrate that tumor-specific methylation patterns in plasma can reveal both the presence and tissue-of-origin of cancer. His research bridges epigenetics, liquid biopsy, and translational oncology, driving new approaches for early cancer detection, minimal residual disease detection, surveillance, classification and monitoring therapy response. At the University of Toronto and Princess Margaret Cancer Centre, his lab investigates how DNA methylation dynamics inform tumor evolution, transposable elements regulation, viral mimicry and treatment response. Dr. De Carvalho’s discoveries have reshaped how scientists and clinicians view the potential of epigenetic biomarkers in precision oncology and pioneered the use of cfDNA methylation for clinical use.

Biography
Arul Chinnaiyan is a globally recognized cancer genomics innovator whose discoveries have reshaped the molecular understanding of prostate and other solid tumors. He led the landmark discovery of the TMPRSS2-ERG gene fusion, the defining molecular event in prostate cancer, which opened the door to genomic subclassification and precision diagnostics now used worldwide. His lab pioneered integrative sequencing approaches that uncover actionable drivers of advanced cancers, leading to the development of clinical tests that match patients to targeted therapies. Chinnaiyans work has generated multiple cancer gene signatures, therapeutic targets, and diagnostic platforms, many of which have translated into routine clinical practice. He also built one of the nations most advanced precision oncology infrastructures, enabling real-time molecular profiling for patients and powering numerous discoveries that bridge basic science with clinical impact. His contributions have shaped the fields of functional genomics, biomarker discovery, and translational oncology, influencing how modern cancer care is delivered. Widely regarded as one of the most impactful physician-scientists of his generation, Chinnaiyans innovations continue to guide therapy decisions, inform drug development, and improve outcomes for patients globally.

Biography
Arul Chinnaiyan is a globally recognized cancer genomics innovator whose discoveries have reshaped the molecular understanding of prostate and other solid tumors. He led the landmark discovery of the TMPRSS2-ERG gene fusion, the defining molecular event in prostate cancer, which opened the door to genomic subclassification and precision diagnostics now used worldwide. His lab pioneered integrative sequencing approaches that uncover actionable drivers of advanced cancers, leading to the development of clinical tests that match patients to targeted therapies. Chinnaiyans work has generated multiple cancer gene signatures, therapeutic targets, and diagnostic platforms, many of which have translated into routine clinical practice. He also built one of the nations most advanced precision oncology infrastructures, enabling real-time molecular profiling for patients and powering numerous discoveries that bridge basic science with clinical impact. His contributions have shaped the fields of functional genomics, biomarker discovery, and translational oncology, influencing how modern cancer care is delivered. Widely regarded as one of the most impactful physician-scientists of his generation, Chinnaiyans innovations continue to guide therapy decisions, inform drug development, and improve outcomes for patients globally.

Biography
Dr. Dennis J. Slamon is a distinguished oncologist and researcher known forhis groundbreaking breast cancer work since the late 1990s. His pioneeringresearch led to trastuzumab (Herceptin), a targeted therapy thatrevolutionized treatment of HER2-positive breast cancer, significantlyimproving survival rates for this aggressive subtype. Dr. Slamon hascontinued to transform cancer research, advancing targeted therapies and precision medicine to improve patient outcomes. His work focuses onidentifying molecular targets for new therapies, tailoring treatments to the specific genetic alterations in tumors. His efforts have impacted notonly breast cancer but other cancers with similar molecular profiles. Throughout his career, Dr. Slamon has received prestigious awards, including the 2019 Lasker-De Bakey Clinical Medical Research Award and the2024 Szent-Györgyi Prize for Progress in Cancer Research. He remains aleader in oncology, dedicated to advancing innovative treatments andimproving the lives of cancer patients worldwide.

Biography
Dr. Liu brings a wealth of experience in developing blood-based biomarkers to predict treatment benefit and outcomes in solid tumors and in developing novel therapeutics to improve survival, with a particular focus in breast cancer. She chaired the Circulating Biomarker Working Group of the Alliance for Clinical Trials in Oncology. She also co-chaired the Correlative Science Working Group and led several multi-institutional clinical trials through the Translational Breast Cancer Research Consortium. Dr. Liu most recently served as professor of oncology and chair of research in the Department of Oncology at Mayo Clinic in Rochester, MN. In her role at Mayo, she also held a dual appointment in the Department of Laboratory Medicine and Pathology and served as co-leader of the Genomics in Action Strategic Priority for the Center of Individualized Medicine.

Biography
Dr. Adrian Lee is the Pittsburgh Foundation Chair and Director of the Institute for Precision Medicine (IPM), a joint effort by UPMC and the University of Pittsburgh to move biomedical research into personalizedwell-being and clinical care. He is also Professor of Pharmacology Chemical Biology and Human Genetics at UPMC Hillman Cancer Center. Dr. Leereceived B. Sc. and Ph. D. degrees in England, and came to San Antonio, Texasfor his postdoctoral studies. He was subsequently recruited to Baylor College of Medicine and to the University of Pittsburgh in 2010. The goalof Dr. Lees research laboratory is to translate basic cell and molecularresearch findings into the understanding and treatment of breast cancer. Dr Lee has published over 180 peer reviewed research articles. His laboratoryis supported by funding from the NIH, Department of Defense, Susan G. Komenfor the Cure, Breast Cancer Research Foundation, and other sources.

Biography
As director of the Division of Medical Oncology at the OSUCCC Dr Rolfo oversee and support specialized units providing care and conducting research for breast, endocrine, gastrointestinal, genitourinary, lung, skin, head and neck cancers and sarcoma. As a thoracic oncologist, I largely focus on lung cancer, mesothelioma and other cancers in the chest area. My goal has always been to blend innovative, personalized treatment plans with the human touch of compassionate care. Dr Rolfo's role at the OSUCCC James also includes serving as associate director for early phase clinical trials. My goal is to ensure a patient-centered approach at every stage of discovery, as breakthroughs we make in the lab can be directly applied to patient care, and observations from patient care continually generate new research questions. Dr Rolfo's research focuses on thoracic oncology, drug development, liquid biopsy and biomarkers of cancer found in the blood, and agnostic tumors defined by molecular or genetic features rather than location in the body. My insights have contributed to the early detection of certain cancers and development of targeted drugs and therapies in these areas. In addition to my clinical and research responsibilities, Dr Rolfo is proud to support the next generation of oncologists and physician-scientists through education and mentorship as a professor of Internal Medicine at The Ohio State University College of Medicine. Dr Rolfo has worked to foster international collaboration and innovation as president of the International Society of Liquid Biopsy (ISLB) and as past chair of the Education Committee at the International Association for Study of Lung Cancer (IASLC). Dr Rolfo has made several contributions to the field through writing book chapters, serving as a book editor and authoring more than 350 scientific articles in peer-reviewed journals, including The New England Journal of Medicine, Lancet Oncology, Cancer Discovery and the Journal of Thoracic Oncology. Dr Rolfo also serve as editor-in-chief of Critical Review in Oncology Hematology.

Biography
As director of the Division of Medical Oncology at the OSUCCC Dr Rolfo oversee and support specialized units providing care and conducting research for breast, endocrine, gastrointestinal, genitourinary, lung, skin, head and neck cancers and sarcoma. As a thoracic oncologist, I largely focus on lung cancer, mesothelioma and other cancers in the chest area. My goal has always been to blend innovative, personalized treatment plans with the human touch of compassionate care. Dr Rolfo's role at the OSUCCC James also includes serving as associate director for early phase clinical trials. My goal is to ensure a patient-centered approach at every stage of discovery, as breakthroughs we make in the lab can be directly applied to patient care, and observations from patient care continually generate new research questions. Dr Rolfo's research focuses on thoracic oncology, drug development, liquid biopsy and biomarkers of cancer found in the blood, and agnostic tumors defined by molecular or genetic features rather than location in the body. My insights have contributed to the early detection of certain cancers and development of targeted drugs and therapies in these areas. In addition to my clinical and research responsibilities, Dr Rolfo is proud to support the next generation of oncologists and physician-scientists through education and mentorship as a professor of Internal Medicine at The Ohio State University College of Medicine. Dr Rolfo has worked to foster international collaboration and innovation as president of the International Society of Liquid Biopsy (ISLB) and as past chair of the Education Committee at the International Association for Study of Lung Cancer (IASLC). Dr Rolfo has made several contributions to the field through writing book chapters, serving as a book editor and authoring more than 350 scientific articles in peer-reviewed journals, including The New England Journal of Medicine, Lancet Oncology, Cancer Discovery and the Journal of Thoracic Oncology. Dr Rolfo also serve as editor-in-chief of Critical Review in Oncology Hematology.

Biography
Dr. Phil Febbo is Chief Scientific and Medical Officer at Veracyte, a global cancer diagnostics company where he remains focused on improving cancer outcomes through the discovery, development, and accessibility of innovative, high-quality molecular diagnostics. He held multiple clinical and scientific roles over 15 years in academia at Dana-Farber, Harvard Medical School, the Whitehead Institute for Genome Research, Duke University, and UCSF where he was Professor of Medicine and Urology. After transitioning to industry, he was Chief Medical Officer at Genomic Health (2013-2018) and Illumina (2018-2023). Dr. Febbo served on the boards of Varian Inc. (Director) and the A CMG Foundation and is currently on the boards of the Reagan Udall Foundation for the FDA (Vice-Chair) and ASC Os Conquer Cancer Foundation. He holds a B. A. in Biology from Dartmouth College, an M. D. from UCSF, completed internal medicine residency at the Brigham and Womens Hospital, and medical oncology fellowship at the DFCI.

Talk
Will send shortly
Will send shortly

Biography
Dr. Emre Baser is trained in medicine at Cumhuriyet University (Türkiye) and Maastricht University (Netherlands), with clinical experience at Justus Liebig University (Germany) Universitatsklinikum Giessen. He brings both clinical expertise and research passion to his role and leads initiatives at the intersection of precision medicine, oncology, molecular pathology, and diagnostics at the Astra Zeneca Medical Affairs team.

Biography
Dr. C. Ola Landgren is a board-certified hematologist-oncologist and he has published more than 500 papers and chapter books with a primary focus on multiple myeloma and its precursor disease. Dr. Landgren's research focuses on mechanisms underlying progression from precursor disease to frank malignancy, underlying mechanisms of disease responseresistance, role of MRD (minimal residual disease) negativity, identification of novel treatment targets, early drug development, and identification of novel biomarkers. His research focus also includes advanced AI based medical tools, and by integrating his translational research efforts he is developing tools for diagnosis, individualized prognosis, and treatment optimization. Prior to joining University of Miami, he served as Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center in New York City, and prior to that he was the Chief of the Multiple Myeloma Section at the National Cancer Institute in Bethesda, MD.

Biography
Dr. Chen is a strategic thinker with proven track record of identifying, developing, and commercializing innovative products in NGS, synthetic biology, and other life science areas. He joined Twist shortly after the company was founded and lead product development for both the synthetic biology and NGS product lines. Dr. Chen conceived and implemented a new product line for NGS that includes synthetic controls for SARS-CoV-2 and other infectious diseases, developed gene synthesis and NGS target enrichment biochemistries, workflow, reagent kits, and infrastructure, and built the companys prototype DNA synthesizer in collaboration with hardware, software, and silicon engineers, which later became a production-scale machine, serving as Twists foundation technology. Dr. Chen is the author of numerous peer-reviewed papers and issued patents in the field of oligonucleotide synthesis and application of synthetic oligonucleotides. He earned his Ph. D. in Chemistry from the University of Wisconsin Madison, and B. Sc. in Chemistry from Peking University in Beijing, China.